



MedGenome to discuss its proprietary cancer immunotherapeutics platform at the San Diego conference

The posters will be presented at the NGS Data Analysis and Informatics Conference, February 18–19, 2016 in San Diego, CA

SAN FRANCISCO, CA, UNITED STATES, February 15, 2016 /EINPresswire.com/ -- MedGenome announced today that they will present 2 posters at the NGS Data Analysis and Informatics Conference, which takes place on February 18–19, 2016 in San Diego, CA.

Details are below:

OncoPept: An integrated platform to develop novel therapeutics and biomarkers for cancer immunotherapy

OncoPept is an integrated platform that interrogates tumor and its microenvironment to discover potential cancer vaccine candidates as therapeutics and biomarkers of response. The platform selects neo-epitopes from genetic alterations including SNVs, indels and fusion genes to generate a library of peptides that are automatically interrogated through multiple prioritization steps to select vaccine candidates to evoke CD4+/CD8+ T-cell response. Additionally OncoPept provides an assessment of the tumor microenvironment by analyzing the immune and the stromal infiltrates within the tumor which are important predictors of response to cancer immunotherapy drugs.

OncoTope: A database of T-cell neo-epitopes from 540 cancer-causing genes mutated and/or overexpressed in 28 different cancers

OncoTope is a database of neo-antigens derived from genetic alterations in 540 cancer-causing genes across 28 different cancer types. The database captures CD4+/CD8+ T-cell neo-epitopes from 563,936 neo-antigens based on their binding affinity to 12-different HLA types and selected based on their expression in cancer cells. Mutated genes are rank ordered according to their T-cell neo-epitope burden.

Both the above products are MedGenome's proprietary platforms, and have been developed in-house for the NGS data analysis and bioinformatics needs.

About MedGenome

MedGenome is a genomics-driven research and diagnostics company with a mission to improve global health by decoding the genetic information contained in an individual's genome. Our powerful genomics solutions accelerate drug discovery research for pharma and biotech companies. Our unique access to genomics data with clinical and phenotypic data provides insights into complex diseases at the genetic and molecular level to facilitate research in personalized healthcare. MedGenome is the market leader for genetic diagnostic testing in India and has worked with thousands of doctors, hospitals, and patients across India by applying Next Generation Sequencing

(NGS) techniques to large disease cohorts in cancer, eye and neurological disorders, diabetes, cardiovascular diseases and rare cancers. For more information, visit us at www.medgenome.com

Forward-looking Statements:

This document contains certain forward-looking statements, other than the statements of research facts contained in this press release are forward looking statements. Terms such as "believe", "estimate", "anticipate", "plan", "predict", "may", "hope", "can", "will", "should", "expect", "intend", "is designed to", "with the intent", "potential", the negative of these words or such other variations thereon or comparable terminology, may indicate forward-looking statements, but their absence does not mean that a statement is not forward-looking. These forward-looking statements speak only as of the date of this press release. The events and circumstances reflected in MedGenome's forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Except as required by applicable law, MedGenome does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

Hiranjith GH
MedGenome
+91-7022020883
email us here

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases.
© 1995-2016 IPD Group, Inc. All Right Reserved.